Cytori Launches Celase® GMP Product
25 März 2015 - 1:00PM
Business Wire
Product to Premier at 2015 ISCT Annual
Meeting
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that it
will formally launch and showcase its new Celase® GMP enzyme at the
2015 International Society for Cellular Therapy (ISCT) annual
meeting on May 27th to 30th in Las Vegas. This will mark the first
time that Cytori has made Celase® GMP available for purchase as a
standalone product.
Celase® is a proprietary enzyme blend that was designed
specifically to optimize Cytori’s automated adipose tissue
dissociation process. Celase® is produced using avian and mammalian
tissue-free raw materials, aseptic processes and sterile filtration
under cGMP guidelines.
“Celase® GMP’s unique, best-in-class formulation is the result
of significant investment made by Cytori,” said Dr. Marc Hedrick,
President and CEO of Cytori Therapeutics. “By making Celase® GMP
broadly available to researchers, we believe Cytori can
simultaneously accelerate the cell therapy field, de-risk clinical
implementation and enhance our cash flows. This represents a clear
win-win scenario for all parties.”
Integrating Celase® GMP into cell isolation study protocols can
facilitate a smooth transition from bench and animal research to
downstream clinical applications. Celase® has been approved by the
U.S. FDA for use in clinical trials evaluating Cytori Cell Therapy™
in patients with chronic heart failure, osteoarthritis of the knee
and hand manifestations of scleroderma.
“Each day our goal is to deliver the best possible health care
to our patients. Using a clinical grade enzyme such as Celase® to
generate a safe and high quality cell output to treat patients
helps us attain this goal,” said Dr. Maurizio Calcagni, Vice
Chairman of the Division of Plastic Surgery and Hand Surgery at
University Hospital Zurich.
“Cytori’s new Celase® GMP product will provide researchers with
superior and unparalleled convenience in their lab, clarity in
their approach, and confidence in their results,” said Russ
Havranek, Director of Global Marketing and Sales at Cytori
Therapeutics.
ISCT attendees are invited to meet with Cytori representatives
at booth #901 to learn more about Celase® GMP. Researchers may also
visit www.celase.com to be informed of announcements and special
offers or send inquiries to celase@cytori.com about purchasing
Celase® GMP directly.
About Cytori Therapeutics, Inc.
Cytori Therapeutics is a late stage cell therapy company
developing laboratory equipment and autologous cell therapies from
adipose tissue to treat a variety of medical conditions. Data from
preclinical studies and clinical trials suggest that Cytori Cell
Therapy™ acts principally by improving blood flow, modulating the
immune system, and facilitating wound repair. As a result, Cytori
Cell Therapy™ may provide benefits across multiple disease states
and can be made available to the physician and patient at the
point-of-care through Cytori’s proprietary technologies and
products. For more information, please visit www.cytori.com.
Cytori Therapeutics, Inc.Shawn Richardson,
1.858.875.5279ir@cytori.com
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024